# Structure of Renal Disease: A Systematic Framework for Clinical Organization ## Learning Objectives By the end of this handout, you will: - Understand the systematic organization of renal disease by anatomic location - Apply a structured approach to differential diagnosis of kidney disease - Recognize how pathophysiologic mechanisms determine clinical presentation - Use this framework to organize clinical thinking during case discussions - Integrate assessment of both structure (anatomy) and function (physiology) ------------------------------------------------------------------------ ## Introduction: Why Organization Matters Nephrology can seem overwhelming with hundreds of disease entities. This handout provides a **structured framework** that organizes all renal disease by: 1. **Anatomic location** — Where in the kidney is the disease? 2. **Pathophysiologic mechanism** — What is the disease doing? 3. **Clinical presentation** — How does the patient present? 4. **Diagnostic approach** — How do we confirm the diagnosis? This systematic approach transforms memorization into logical clinical reasoning. ------------------------------------------------------------------------ ## PART 1: STRUCTURAL ANATOMY AND ASSESSMENT ### I. GROSS (MACROSCOPIC) KIDNEY ANATOMY **Definition:** Large-scale kidney architecture visible on imaging (ultrasound, CT, MRI) #### A. Size Assessment - **Normal:** 11-12 cm length; 120-170 g weight per kidney - **Enlarged kidneys:** - Polycystic kidney disease (ADPKD, ARPKD) - Early diabetic nephropathy - Lymphoma, leukemia - Amyloidosis - **Shrunken kidneys:** - Chronic kidney disease (end-stage fibrosis) - Chronic glomerulonephritis - Chronic pyelonephritis - Renal infarction (old) #### B. Cystic Lesions - **Single cysts:** Benign; common in older adults - **Multiple cysts:** - Autosomal dominant polycystic kidney disease (ADPKD) → progressive to ESRD - Autosomal recessive polycystic kidney disease (ARPKD) → neonatal presentation - Simple cysts (benign variant) - **Cystic complications:** Infection, hemorrhage, rupture → pain, hematuria #### C. Masses - **Solid tumors:** - Renal cell carcinoma (most common) - Oncocytoma, angiomyolipoma (benign variants) - Lymphoma (can be primary or secondary) - **Assessment:** Size \>3 cm concerning; vascular invasion indicates aggressive disease #### D. Drainage Assessment - **Hydronephrosis:** Dilation of renal pelvis/calyces from obstruction - Causes: Stones, strictures, malignancy, fibrosis - Risk: Progressive kidney damage if unrelieved - **Atrophic kidneys with normal drainage:** Chronic disease (fibrosis, atrophy) #### E. Assessment Methods - **Ultrasound:** First-line (no radiation); assesses size, echogenicity, hydronephrosis, doppler flow - **CT (non-contrast):** Gold standard for stones; excellent for masses - **MRI:** Best for patients avoiding radiation; limited use in severe CKD (gadolinium risk) - **Doppler ultrasound:** Assesses renal artery flow; screens for renal artery stenosis ------------------------------------------------------------------------ ### II. MICROANATOMY (HISTOLOGIC STRUCTURE) **Definition:** Tissue-level kidney architecture requiring kidney biopsy #### A. The Nephron and Glomerular Changes **Normal Structure:** - Glomerulus: Fenestrated endothelium + basement membrane + podocytes - Capillaries: 50 m² filtration surface area - Mesangium: Structural support, immune clearance **Pathologic Changes Seen on Biopsy:** - **Proliferative lesions:** Cell multiplication (mesangial, endothelial) - Examples: IgA nephropathy, MPGN, post-infectious GN - Significance: Active inflammation; often responsive to treatment - **Membranous changes:** Basement membrane thickening - Examples: Membranous nephropathy, diabetic disease - Significance: Structural damage; may indicate chronic process - **Sclerosis:** Fibrosis/scarring of glomeruli - Examples: FSGS, late diabetic disease, chronic hypertension - Significance: Irreversible damage; worse prognosis - **Crescent formation:** Extracapillary proliferation (ominous sign) - Examples: RPGN, ANCA vasculitis, anti-GBM disease - Significance: Rapidly progressive; requires urgent treatment #### B. Tubular Changes - **Acute tubular injury:** Cell swelling, necrosis (acute tubular necrosis) - **Chronic changes:** Atrophy, fibrosis (tubular atrophy and interstitial fibrosis—TAIF) - **Cast formation:** Proteinous or cellular casts within tubules #### C. Interstitial Changes - **Interstitial inflammation:** Acute interstitial nephritis (AIN) - **Interstitial fibrosis:** Progressive scarring (TAIF—most common final pathway of all CKD) - **Immune infiltrates:** Cell type indicates cause (eosinophils in drug AIN, lymphocytes in infection) #### D. Vascular Changes - **Intimal fibrosis:** Narrowed arterioles (hypertensive/diabetic injury) - **Arterial stenosis:** Renal artery narrowing (atherosclerotic or fibromuscular dysplasia) - **Thrombosis:** Vessel occlusion (thrombotic microangiopathy) ------------------------------------------------------------------------ ## PART 2: PHYSIOLOGIC FUNCTION AND DYSFUNCTION ### I. GLOMERULAR FILTRATION (GFR = Kidney’s Primary Job) **Normal Function:** - GFR ~100-120 mL/min/1.73m² (young adult) - Filters 180 L/day while retaining proteins and cells - Determined by: Hydrostatic pressure, oncotic pressure, filtration coefficient **Mechanisms of GFR Reduction:** | Mechanism | Pathophysiology | Examples | |----|----|----| | **Decreased filtration pressure** | Low perfusion pressure | Hypovolemia, cardiorenal syndrome, renal artery stenosis | | **Increased downstream pressure** | Obstruction of tubular flow | Stones, strictures, malignancy | | **Loss of filtration barrier** | Structural damage to glomerulus | Glomerulonephritis, diabetic disease | | **Loss of nephrons** | Permanent nephron loss | End-stage disease, surgical loss | ------------------------------------------------------------------------ ### II. TUBULAR FUNCTION DISORDERS **Tubular Reabsorption Defects:** #### A. Sodium Handling - **Normal:** Proximal tubule reabsorbs 65% of filtered Na+ - **Pathology:** Loop diuretics block ascending limb; thiazides block DCT - **Clinical result:** Salt wasting or salt retention depending on location/medication #### B. Water Balance - **Normal:** ADH allows water reabsorption in collecting duct - **Pathology:** - Central diabetes insipidus: Inadequate ADH production - Nephrogenic diabetes insipidus: Kidney unresponsive to ADH - SIADH: Excess ADH → water retention - **Clinical result:** Polyuria (DI) or hyponatremia (SIADH) #### C. Electrolyte Handling (K+, Mg2+, Ca2+, PO4³⁻) - **Potassium:** DCT and collecting duct excrete; aldosterone increases excretion - **Magnesium:** Thick ascending limb reabsorbs; PPI use causes wasting - **Calcium:** PTH increases DCT reabsorption; varies inversely with sodium - **Phosphate:** Normally filtered; PTH decreases proximal reabsorption - **Clinical result:** Hyperkalemia in ESRD, hypomagnesemia from PPIs, secondary hyperparathyroidism in CKD #### D. Acid-Base Regulation - **Proximal tubule:** Reabsorbs filtered HCO₃⁻ (99% normally) - **Distal tubule/collecting duct:** Secretes H+ via intercalated cells - **Pathology:** Renal tubular acidosis (RTA) from impaired H+ or HCO₃⁻ handling - **Clinical result:** Non-anion-gap metabolic acidosis despite normal anion gap #### E. Protein/Albumin Reabsorption - **Normal:** Proximal tubule reabsorbs virtually all filtered proteins (\<150 mg/day urine) - **Pathology:** Proteinuria occurs when filtered protein exceeds reabsorptive capacity - **Significance:** Proteinuria is both sign of kidney damage AND risk factor for progression #### F. Glucose Handling - **Normal:** All filtered glucose reabsorbed; urine glucose = 0 - **Pathology:** Glucosuria indicates either hyperglycemia or proximal dysfunction - **Clinical result:** Diabetes mellitus or Fanconi syndrome #### G. Organic Acid Handling - **Normal:** Uric acid secreted in proximal tubule - **Pathology:** Impaired secretion → hyperuricemia; increased reabsorption possible - **Clinical result:** Gout risk increases in CKD; hyperuricemia promotes stone formation ------------------------------------------------------------------------ ### III. ENDOCRINE FUNCTIONS #### A. Blood Pressure Regulation - **Mechanism:** RAAS activation by decreased renal perfusion - **Pathophysiology:** Renin → Angiotensin II → Vasoconstriction & aldosterone → sodium retention - **Failure in CKD:** Inability to control extracellular volume → hypertension #### B. Erythropoietin Production - **Normal:** Peritubular fibroblasts produce EPO in response to hypoxia - **Pathophysiology:** EPO deficiency in CKD → anemia (normocytic, hypoproliferative) - **Clinical result:** Hematocrit drops ~10 points in ESRD without treatment #### C. Vitamin D Synthesis - **Normal:** Proximal tubule converts 25-OH vitamin D → active 1,25-dihydroxy vitamin D - **Pathophysiology:** Impaired conversion in CKD despite normal 25-OH levels - **Clinical result:** Secondary hyperparathyroidism from low calcitriol #### D. Metabolic Functions - **Gluconeogenesis:** During fasting; impaired in CKD - **Ammonia production:** Critical for acid excretion; reduced in CKD - **Drug metabolism:** Renally cleared drugs accumulate in CKD ------------------------------------------------------------------------ ## PART 3: PATHOPHYSIOLOGY — DISEASE MECHANISMS ### I. CHRONIC KIDNEY DISEASE (CKD) **Definition:** Progressive, irreversible loss of kidney function staged by eGFR **Two Main Categories:** #### A. Glomerular Diseases **Mechanism:** Primary immune-mediated damage to glomerulus - **Examples:** - IgA nephropathy (hematuria, progressive) - Membranous nephropathy (nephrotic proteinuria) - FSGS (progressive proteinuria) - Lupus nephritis (systemic disease) - ANCA vasculitis (rapidly progressive) **Presentation:** Often presents with proteinuria ± hematuria #### B. Interstitial/Tubular Disease **Mechanism:** Primary damage to tubules and interstitium, glomeruli secondary - **Examples:** - Diabetic nephropathy (progressive, but mixed glomero-tubular) - Hypertensive nephrosclerosis (chronic hypertension damage) - Chronic pyelonephritis (recurrent infections) - Drug-induced CKD (NSAIDs, lithium, amphotericin) - Reflux nephropathy (vesicoureteral reflux) **Presentation:** May present without proteinuria initially; later develops as glomerulosclerosis occurs #### C. Final Common Pathway: TAIF **TAIF = Tubular Atrophy and Interstitial Fibrosis** - **Significance:** ALL chronic diseases progress to TAIF if untreated - **Mechanism:** Fibroblast proliferation, myofibroblast transformation, collagen deposition - **Implication:** Irreversible once established; can’t regain function once TAIF prominent ------------------------------------------------------------------------ ### II. ACUTE KIDNEY INJURY (AKI) **Definition:** Acute loss of kidney function, potentially reversible **Three Main Categories:** #### A. Prerenal AKI (55-60% of cases) **Mechanism:** Decreased renal perfusion without direct kidney damage - **Causes:** - Hypovolemia: Hemorrhage, dehydration, GI losses, burns - Decreased effective circulating volume: CHF, cirrhosis, nephrotic syndrome - Systemic vasodilation: Sepsis, medications - Renal vasoconstriction: ACEi/ARB in specific patients, NSAIDs - Aortic dissection, renal artery stenosis **Key Finding:** FENa \<1% (kidney conserves sodium appropriately) **Prognosis:** Reversible with treatment of underlying cause; responds to fluid resuscitation #### B. Intrinsic (Parenchymal) AKI (35-40% of cases) **B1. Acute Tubular Necrosis (ATN)** - **Mechanism:** Direct injury to tubular epithelium - **Causes:** - **Ischemic:** Prolonged renal hypoperfusion (shock, severe dehydration) - **Nephrotoxic:** Medications (aminoglycosides, amphotericin B, cisplatin), contrast dye, myoglobin (rhabdo), hemoglobin (massive hemolysis), uric acid (tumor lysis) - **Key Finding:** FENa \>2%, muddy brown granular casts - **Prognosis:** Reversible with appropriate supportive care; typically recovers in 1-3 weeks **B2. Acute Interstitial Nephritis (AIN)** - **Mechanism:** Immune-mediated inflammation of interstitium and tubules - **Causes:** Medications (NSAIDs, antibiotics—especially beta-lactams, PPIs), infections, autoimmune - **Key Finding:** Eosinophiluria, pyuria without bacteria - **Prognosis:** Often reversible if offending agent removed promptly; permanent damage if delayed **B3. Acute Glomerulonephritis** - **Mechanism:** Immune complex deposition or vasculitis affecting glomeruli - **Causes:** Post-infectious GN, ANCA vasculitis, anti-GBM disease, lupus, IgA nephropathy (acute exacerbation) - **Key Finding:** RBC casts, dysmorphic RBCs, hematuria + proteinuria - **Prognosis:** Varies by type; RPGN requires urgent plasma exchange; others may recover with immunosuppression **B4. Other Intrinsic Causes** - **Vascular:** Renal infarction, thrombosis, dissection, thrombotic microangiopathy (HUS, TTP, scleroderma) **Key Finding:** Elevated LDH, low platelets, schistocytes on smear in microangiopathy #### C. Postrenal AKI (5% of cases) **Mechanism:** Urinary obstruction preventing urine flow - **Causes:** - Upper urinary tract: Stones, strictures, malignancy, fibrosis - Lower urinary tract: BPH, urethral stricture, functional (severe constipation) - **Key Finding:** Hydronephrosis on ultrasound - **Prognosis:** Excellent if decompressed promptly; permanent damage if prolonged obstruction **Clinical Pearl:** Always ask “Did the AKI develop suddenly in previously well kidneys (AKI) or is there a history of progressive kidney disease (CKD)?” Baseline creatinine is essential for interpretation. ------------------------------------------------------------------------ ### III. HYPERTENSION IN KIDNEY DISEASE **Two-Way Relationship:** 1. **Hypertension causes kidney disease** → chronic hypertensive injury → nephrosclerosis 2. **Kidney disease causes hypertension** → inability to excrete sodium → volume expansion and RAAS activation **Mechanisms:** - **Renin-angiotensin-aldosterone system:** Renal hypoperfusion → renin release → vasoconstriction and sodium retention - **Volume expansion:** Impaired sodium excretion in CKD → fluid retention → hypertension - **Endothelial dysfunction:** Vascular injury from proteinuria and hemodynamic changes **Clinical Implications:** - Tight BP control slows CKD progression - ACEi/ARB first-line (reduce intraglomerular pressure, reduce proteinuria) - Salt restriction critical for volume-dependent hypertension ------------------------------------------------------------------------ ## PART 4: CLINICAL INTEGRATION — USING THE FRAMEWORK ### How to Organize Your Thinking About Any Renal Disease **Step 1: Assess STRUCTURE (What does it look like?)** - Is the kidney enlarged, normal, or shrunken? - Are there cysts, masses, or obstruction? - Biopsy findings? (If available) **Step 2: Assess PHYSIOLOGY (What is broken?)** - Is GFR decreased? (By how much? How fast?) - Is there proteinuria? (Glomerular disease likely) - Are there electrolyte abnormalities? (Tubular dysfunction likely) - Is there acid-base disturbance? (Tubular secretion problem likely) **Step 3: Determine PATHOPHYSIOLOGY (Why is it broken?)** - Is this a glomerular disease? (RBC casts, proteinuria, hematuria) - Is this tubular/interstitial disease? (Electrolyte wasting, minimal proteinuria initially) - Is this acute or chronic? (Rapidly rising Cr = acute; slow decline = chronic) - Is this reversible (AKI) or permanent (CKD)? **Step 4: Apply CLINICAL KNOWLEDGE (What do we do about it?)** - What is the cause? (Needs specific treatment) - Is it progressive? (Needs prevention of progression) - Are there complications? (Hypertension, proteinuria, anemia, bone disease) ### Example Case Integration **Case:** 65-year-old with 10-year history of hypertension, now eGFR 35 mL/min, creatinine 2.0 (baseline 1.0 three years ago). **Structure:** Kidney ultrasound shows normal-sized kidneys with normal echogenicity, no hydronephrosis **Physiology:** eGFR 35 (Stage 3b CKD); spot protein/creatinine 2.5 g/g (heavy proteinuria) **Pathophysiology:** Chronic disease (slow creatinine rise over 3 years); glomerular disease component (heavy proteinuria) overlaying hypertensive/diabetic injury **Clinical:** Likely hypertensive nephrosclerosis with diabetic overlap (if diabetic), or primary glomerular disease. Needs: tight BP control, ACEi/ARB, low sodium diet, monitoring for complications. ------------------------------------------------------------------------ ## Quick Reference Tables ### Anatomic Patterns in Kidney Disease | Location | Disease Type | Example | Presentation | |----|----|----|----| | **Glomerulus** | Glomerulonephritis | IgA nephropathy, FSGS, membranous | Hematuria, proteinuria, RBC casts | | **Tubule** | Tubular dysfunction | Renal tubular acidosis, Bartter syndrome | Electrolyte abnormalities, minimal proteinuria | | **Interstitium** | Interstitial nephritis | Drug-induced AIN, chronic pyelonephritis | Pyuria, eosinophiluria, sometimes fever/rash | | **Vasculature** | Vascular disease | Renal artery stenosis, renal infarction | Hypertension, AKI, flank pain | | **Collecting System** | Obstruction | Kidney stone, malignancy | Hydronephrosis, obstruction on imaging | ### Progression Patterns | Pattern | Reversibility | Examples | Prognosis | |----|----|----|----| | **Acute (days-weeks)** | Reversible if treated | ATN, AIN, prerenal | Can return to baseline | | **Progressive chronic (months-years)** | Partially reversible | Early CKD, nephrotic syndrome | Slowing possible with treatment | | **End-stage (years)** | Irreversible | ESRD with TAIF | Requires RRT | ------------------------------------------------------------------------ ## Summary: The “Big Picture” Framework **All kidney disease fits into this structure:** 1. **Where:** Glomerulus, tubule, interstitium, vessels, or collecting system? 2. **How bad:** Normal → CKD 1 → CKD 2 → CKD 3a → CKD 3b → CKD 4 → CKD 5/ESRD? 3. **How fast:** Acute (reversible) or chronic (progressive)? 4. **Why:** Specific diagnosis determines specific treatment 5. **What next:** Prevent progression, manage complications, prepare for RRT if needed ------------------------------------------------------------------------ ## Clinical Pearl Summary - **All CKD ultimately progresses to TAIF** (tubular atrophy and interstitial fibrosis) — the final common pathway - **Proteinuria is both a marker and driver of progression** — reduce it aggressively - **Tight BP control is universal therapy** — all CKD patients benefit - **Early intervention is key** — once ESRD develops, only RRT or transplant available - **Know the baseline creatinine** — it’s the most important number you’re missing ------------------------------------------------------------------------ ## Practice Integration Questions 1. **Distinguish:** Glomerular disease typically presents with \_\_\_\_\_ and \_\_\_\_\_; tubular disease may have \_\_\_\_\_ but preserve \_\_\_\_\_. 2. **Classify:** A patient with hypertension, hypokalemia, metabolic alkalosis, and elevated renin likely has \_\_\_\_\_ dysfunction at the \_\_\_\_\_ level. 3. **Predict:** Progressive CKD with rising proteinuria will eventually develop complications: \_\_\_\_\_, \_\_\_\_\_, \_\_\_\_\_, and \_\_\_\_\_. ------------------------------------------------------------------------ ## Related Handouts - nephrology quick start guide — Foundational concepts - nephrology glossary student handout — 100 terms explained - nephrology study topics guide — Reading recommendations ------------------------------------------------------------------------ *This framework transforms nephrology from memorization of hundreds of diseases into systematic, logical clinical reasoning.* --- [Website version](https://urinenephrology.org/student-resources/foundations/structure-of-renal-disease-student-handout.html) · Markdown synchronized October 3, 2026.